# Vuzix Corp: financial statements, quarterly

VUZI · Nasdaq · CIK 1463972 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vuzi.md) · [Financials](/companies/vuzi/financials.md) · [Filings](/companies/vuzi/filings.md) · [Insiders](/companies/vuzi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vuzi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.2](/filings/0001104659-26-027163.md) | [1.1](/filings/0001104659-26-027163.md) | [2.0](/filings/0001104659-26-027163.md) | [1.1](/filings/0001104659-26-027163.md) | [1.4](/filings/0001104659-26-027163.md) | [1.3](/filings/0001104659-26-027163.md) | [1.6](/filings/0001104659-26-061153.md) | [1.3](/filings/0001104659-26-095889.md) | [1.2](/filings/0001104659-26-027163.md) | [2.2](/filings/0001104659-26-027163.md) | [1.4](/filings/0001104659-26-061153.md) | [1.1](/filings/0001104659-26-095889.md) |
| Cost of revenue | $m | [2.4](/filings/0001558370-24-015704.md) | [5.3 d](/filings/0001104659-26-027163.md) | [2.1](/filings/0001558370-25-007368.md) | [1.4](/filings/0001558370-25-011550.md) | [1.6](/filings/0001104659-25-111263.md) | [6.2 d](/filings/0001104659-26-027163.md) | [1.8](/filings/0001104659-26-061153.md) | [2.1](/filings/0001104659-26-095889.md) | [1.6](/filings/0001104659-25-111263.md) | [1.9 d](/filings/0001104659-26-027163.md) | [1.8](/filings/0001104659-26-061153.md) | [1.8](/filings/0001104659-26-095889.md) |
| Gross profit | $m | [(0.2)](/filings/0001104659-26-027163.md) | [(4.2)](/filings/0001104659-26-027163.md) | [(0.1)](/filings/0001104659-26-027163.md) | [(0.3)](/filings/0001104659-26-027163.md) | [(0.3)](/filings/0001104659-26-027163.md) | [(5.0)](/filings/0001104659-26-027163.md) | [(0.3)](/filings/0001104659-26-061153.md) | [(0.8)](/filings/0001104659-26-095889.md) | [(0.4)](/filings/0001104659-26-027163.md) | [0.4](/filings/0001104659-26-027163.md) | [(0.4)](/filings/0001104659-26-061153.md) | [(0.6)](/filings/0001104659-26-095889.md) |
| Research and development | $m | [2.9](/filings/0001558370-24-015704.md) | [3.5 d](/filings/0001104659-26-027163.md) | [2.7](/filings/0001558370-25-007368.md) | [2.4](/filings/0001558370-25-011550.md) | [2.3](/filings/0001104659-25-111263.md) | [2.2 d](/filings/0001104659-26-027163.md) | [2.6](/filings/0001104659-26-061153.md) | [2.6](/filings/0001104659-26-095889.md) | [2.9](/filings/0001104659-25-111263.md) | [4.5 d](/filings/0001104659-26-027163.md) | [3.0](/filings/0001104659-26-061153.md) | [3.1](/filings/0001104659-26-095889.md) |
| Operating income | $m | [(11.4)](/filings/0001558370-24-015704.md) | [(20.4) d](/filings/0001104659-26-027163.md) | [(10.1)](/filings/0001558370-25-007368.md) | [(40.7)](/filings/0001558370-25-011550.md) | [(9.3)](/filings/0001104659-25-111263.md) | [(13.8) d](/filings/0001104659-26-027163.md) | [(8.8)](/filings/0001104659-26-061153.md) | [(7.9)](/filings/0001104659-26-095889.md) | [(7.5)](/filings/0001104659-25-111263.md) | [(8.4) d](/filings/0001104659-26-027163.md) | [(7.2)](/filings/0001104659-26-061153.md) | [(7.8)](/filings/0001104659-26-095889.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(11.0)](/filings/0001104659-26-027163.md) | [(19.9)](/filings/0001104659-26-027163.md) | [(10.0)](/filings/0001104659-26-027163.md) | [(40.6)](/filings/0001104659-26-027163.md) | [(9.2)](/filings/0001104659-26-027163.md) | [(13.7)](/filings/0001104659-26-027163.md) | [(8.6)](/filings/0001104659-26-061153.md) | [(7.7)](/filings/0001104659-26-095889.md) | [(7.4)](/filings/0001104659-26-027163.md) | [(8.6)](/filings/0001104659-26-027163.md) | [(7.1)](/filings/0001104659-26-061153.md) | [(7.6)](/filings/0001104659-26-095889.md) |
| Diluted EPS | $ per share | [(0.17)](/filings/0001104659-26-027163.md) | [(0.32)](/filings/0001104659-26-027163.md) | [(0.16)](/filings/0001104659-26-027163.md) | [(0.62)](/filings/0001104659-26-027163.md) | [(0.14)](/filings/0001104659-26-027163.md) | [(0.16)](/filings/0001104659-26-027163.md) | [(0.11)](/filings/0001104659-26-061153.md) | [(0.10)](/filings/0001104659-26-095889.md) | [(0.09)](/filings/0001104659-26-027163.md) | [(0.12)](/filings/0001104659-26-027163.md) | [(0.09)](/filings/0001104659-26-061153.md) | [(0.09)](/filings/0001104659-26-095889.md) |
| Basic EPS | $ per share | [(0.17)](/filings/0001104659-26-027163.md) | [(0.32)](/filings/0001104659-26-027163.md) | [(0.16)](/filings/0001104659-26-027163.md) | [(0.62)](/filings/0001104659-26-027163.md) | [(0.14)](/filings/0001104659-26-027163.md) | [(0.16)](/filings/0001104659-26-027163.md) | [(0.11)](/filings/0001104659-26-061153.md) | [(0.10)](/filings/0001104659-26-095889.md) | [(0.09)](/filings/0001104659-26-027163.md) | [(0.12)](/filings/0001104659-26-027163.md) | [(0.09)](/filings/0001104659-26-061153.md) | [(0.09)](/filings/0001104659-26-095889.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [38.0](/filings/0001558370-23-018554.md) | [26.6](/filings/0001558370-25-002903.md) | [16.5](/filings/0001558370-24-007591.md) | [9.9](/filings/0001558370-24-012237.md) | [14.3](/filings/0001558370-24-015704.md) | [18.2](/filings/0001104659-26-027163.md) | [15.2](/filings/0001558370-25-007368.md) | [17.5](/filings/0001558370-25-011550.md) | [22.6](/filings/0001104659-25-111263.md) | [21.2](/filings/0001104659-26-095889.md) | [20.2](/filings/0001104659-26-061153.md) | [17.3](/filings/0001104659-26-095889.md) |
| Current assets | $m | [59.6](/filings/0001558370-23-018554.md) | [41.5](/filings/0001558370-25-002903.md) | [32.7](/filings/0001558370-24-007591.md) | [24.7](/filings/0001558370-24-012237.md) | [28.7](/filings/0001558370-24-015704.md) | [26.7](/filings/0001104659-26-027163.md) | [22.4](/filings/0001558370-25-007368.md) | [23.3](/filings/0001558370-25-011550.md) | [28.2](/filings/0001104659-25-111263.md) | [27.2](/filings/0001104659-26-095889.md) | [24.8](/filings/0001104659-26-061153.md) | [21.9](/filings/0001104659-26-095889.md) |
| Total assets | $m | [101](/filings/0001558370-23-018554.md) | [86.1](/filings/0001558370-25-002903.md) | [77.0](/filings/0001558370-24-007591.md) | [38.2](/filings/0001558370-24-012237.md) | [41.8](/filings/0001558370-24-015704.md) | [39.4](/filings/0001104659-26-027163.md) | [35.8](/filings/0001558370-25-007368.md) | [36.9](/filings/0001558370-25-011550.md) | [42.5](/filings/0001104659-25-111263.md) | [40.1](/filings/0001104659-26-095889.md) | [38.4](/filings/0001104659-26-061153.md) | [35.2](/filings/0001104659-26-095889.md) |
| Current liabilities | $m | [5.1](/filings/0001558370-23-018554.md) | [5.2](/filings/0001558370-25-002903.md) | [3.5](/filings/0001558370-24-007591.md) | [2.6](/filings/0001558370-24-012237.md) | [2.2](/filings/0001558370-24-015704.md) | [2.1](/filings/0001104659-26-027163.md) | [2.9](/filings/0001558370-25-007368.md) | [3.0](/filings/0001558370-25-011550.md) | [4.0](/filings/0001104659-25-111263.md) | [4.9](/filings/0001104659-26-095889.md) | [4.0](/filings/0001104659-26-061153.md) | [3.8](/filings/0001104659-26-095889.md) |
| Total liabilities | $m | [5.3](/filings/0001558370-23-018554.md) | [5.4](/filings/0001558370-25-002903.md) | [3.8](/filings/0001558370-24-007591.md) | [2.8](/filings/0001558370-24-012237.md) | [2.3](/filings/0001558370-24-015704.md) | [2.1](/filings/0001104659-26-027163.md) | not reported | not reported | [4.6](/filings/0001104659-25-111263.md) | [5.4](/filings/0001104659-26-095889.md) | [4.4](/filings/0001104659-26-061153.md) | [4.1](/filings/0001104659-26-095889.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [95.7](/filings/0001558370-24-015704.md) | [80.8](/filings/0001104659-26-027163.md) | [73.1](/filings/0001558370-25-011550.md) | [35.4](/filings/0001104659-25-111263.md) | [39.6](/filings/0001104659-25-111263.md) | [37.3](/filings/0001104659-26-095889.md) | [32.8](/filings/0001104659-26-095889.md) | [28.9](/filings/0001104659-26-095889.md) | [27.9](/filings/0001104659-25-111263.md) | [24.7](/filings/0001104659-26-095889.md) | [24.0](/filings/0001104659-26-095889.md) | [21.1](/filings/0001104659-26-095889.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(8,048) d](/filings/0001558370-24-015704.md) | [(6,144) d](/filings/0001104659-26-027163.md) | [(8,805)](/filings/0001558370-25-007368.md) | [(5,635) d](/filings/0001558370-25-011550.md) | [(5,277) d](/filings/0001104659-25-111263.md) | [(4,022) d](/filings/0001104659-26-095889.md) | [(3,454)](/filings/0001104659-26-061153.md) | [(4,788) d](/filings/0001104659-26-095889.md) | [(4,993) d](/filings/0001104659-25-111263.md) | [(5,554) d](/filings/0001104659-26-095889.md) | [(5,555)](/filings/0001104659-26-061153.md) | [(6,597) d](/filings/0001104659-26-095889.md) |
| Capital expenditure | $k | [834 d](/filings/0001558370-24-015704.md) | [1,715 d](/filings/0001104659-26-027163.md) | [101](/filings/0001558370-25-007368.md) | [828 d](/filings/0001558370-25-011550.md) | [199 d](/filings/0001104659-25-111263.md) | [230 d](/filings/0001104659-26-027163.md) | [613](/filings/0001104659-26-061153.md) | [727 d](/filings/0001104659-26-095889.md) | [318 d](/filings/0001104659-25-111263.md) | [355 d](/filings/0001104659-26-027163.md) | [996](/filings/0001104659-26-061153.md) | [217 d](/filings/0001104659-26-095889.md) |
| Share repurchases | $k | [0.0 d](/filings/0001558370-24-015704.md) | [0.0 d](/filings/0001104659-26-027163.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [63.8](/filings/0001558370-23-018554.md) | [63.2](/filings/0001558370-24-007591.md) | [63.2](/filings/0001558370-24-012237.md) | [63.3](/filings/0001558370-24-015704.md) | [64.7](/filings/0001558370-25-007368.md) | [65.8](/filings/0001558370-25-011550.md) | [67.8](/filings/0001104659-25-111263.md) | [76.2](/filings/0001104659-26-061153.md) | [76.5](/filings/0001104659-26-095889.md) | [77.5](/filings/0001104659-25-111263.md) | [81.9](/filings/0001104659-26-061153.md) | [83.7](/filings/0001104659-26-095889.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 84,414,230 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001104659-26-095889.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.